AbSeek™: AI-Driven Computational Methods for Antibody Design and Optimization

Industry Insight

Antibody drug discovery is moving from the traditional “library construction–screening–validation–iterative trial-and-error” workflow toward predictive design powered by computational biology and structural biology. For monoclonal antibodies, bispecific antibodies, ADC-related antibodies, and nanobodies, R&D teams need more than binding candidates. They need early-stage assessment of affinity, immunogenicity risk, stability, aggregation propensity, and multi-chain assembly risk. Without practical computational methods, a large share of experimental resources may be spent validating low-value candidates, while developability liabilities often emerge only at later stages.

Industrial antibody discovery therefore requires more than isolated algorithms. It needs an integrated computational framework that connects sequence, structure, function, and developability. Only when AI models are linked with real experimental data, structure prediction, affinity measurement, and developability validation can computational outputs reliably inform candidate prioritization and downstream experimental decisions.

Introduction

The AbSeek^TM intelligent computing platform from Cyagen is built around artificial intelligence and structural biology. It provides a computational framework covering key stages of antibody design, from sequence-level assessment to developability optimization. By establishing quantitative links across “sequence → structure → function → developability,” AbSeek^TM helps shift antibody discovery from experiment-heavy trial and error toward computation-guided design.

The Computational Shift in Antibody Design: From Empirical Trial and Error to Data-Driven Prediction

Antibodies are complex biomolecules whose key properties, including affinity, stability, and immunogenicity risk, are fundamentally determined by amino acid sequence and three-dimensional structure. Conventional experiment-driven workflows face several persistent bottlenecks:

• Difficulty linking sequence to function:Binding capability cannot be reliably inferred from sequence alone, often requiring extensive SPR/BLI validation.
• Complex coupling between structure and developability:Aggregation risk and insufficient thermal stability usually require stepwise SEC-HPLC, DSC, and related assays, making late-stage remediation costly.
• High computational complexity in multi-antibody formats:For bispecific and multispecific antibodies, light/heavy-chain mispairing and epitope synergy remain difficult to predict and often rely on experience-driven mutant construction.

The core value of AbSeek^TM lies in using AI-powered computational methods to quantify the relationships among antibody sequence, structure, function, and developability, enabling candidate screening to become more predictable, rankable, and experimentally verifiable at earlier stages.

The Core Architecture of AbSeek^TM Computational Methods: Deep Integration of Data, Models, and Algorithms

AbSeek^TM is not a single-purpose tool. It is an antibody computing framework built on multi-source data, multimodal model integration, and algorithmic coverage across multiple development stages.

1. Data Foundation: Building an Industrial-Grade Antibody Computing Database

The accuracy of computational methods starts with high-quality data. AbSeek^TM integrates public databases with proprietary experimental data from Cyagen, reducing the risk that models trained only on public data become disconnected from real-world R&D scenarios.

• Deep mining of public datasets:The platform analyzes large-scale antibody sequences from OAS (Observed Antibody Space) to extract sequence features and mutation patterns of human immunoglobulin gene families such as IGHV, IGKV, and IGLV. It also leverages 10,000+ structurally resolved antibody–antigen complexes from SAbDab to support spatial conformation prediction and interface modeling.
• Proprietary experimental data:AbSeek^TM incorporates millions of experimental records accumulated through Cyagen’s antibody development programs, including more than one thousand antibody expression and affinity datasets, hundreds of developability and in vivo efficacy-related datasets, fully human antibody sequences from HUGO mouse platforms, and bispecific antibody mispairing datasets. These data make model training more aligned with industrial needs.

The combination of public and proprietary data strengthens the industrial adaptability of AbSeek^TM. In affinity prediction tasks, including scenarios such as ADC-related antibodies, the model reduces prediction deviation by 40% compared with models trained only on public data.

2. Model Architecture: Multimodal AI Models Working Together

AbSeek^TM adopts a multimodal architecture that combines natural language processing and structural biology, calculating antibody properties through sequence semantics, spatial conformation, and multi-task learning.

• NLP models:These models analyze antibody sequence features. In humanness assessment, Transformer-based architectures learn the sequence semantics of human immunoglobulins and generate a scoring framework for evaluating antibody humanness.
• Structure prediction models:Antibody–antigen complex prediction algorithms based on AlphaFold3-like architectures model the binding conformation between antibody CDR regions and antigen epitopes, providing structural input for affinity calculation.
• Multi-task learning models:Multiple tasks, including PTM risk site analysis and developability assessment, are jointly trained to enable multi-attribute calculation from a single sequence and improve model generalization.

Four Key Computational Modules for Antibody Design Workflows

The computational methods in AbSeek^TM are designed around practical pain points in antibody discovery. Four targeted modules provide quantitative indicators for candidate screening and optimization.

1. Antibody Humanness Assessment: A Pre-Screening Layer for Immunogenicity Risk

Antibody humanness is closely associated with the risk of anti-drug antibody (ADA) responses. Traditional humanization assessment often relies on database comparison and subsequent experimental validation, with limited global quantitative guidance. AbSeek^TM uses NLP-driven methods for rapid assessment.

• Computational principle:The model extracts amino acid sequence features around the antibody variable region (Fv) and related sequence segments, identifies species-related sequence patterns and similarity to human immunoglobulin sequences, and outputs a 0–1 humanness score. A score of ≥0.95 can be used as a reference threshold for low immunogenicity risk.
• Computational advantage:The workflow does not require the upfront construction of large numbers of humanized mutants. It can score 100 sequences within 10 seconds, making it suitable for early candidate pre-screening.
• Experimental validation:In a PD-L1 antibody project, AbSeek^TM identified three sequences with scores ≥0.95. Subsequent huHSC mouse experiments showed ADA incidence below 5% for these sequences, whereas sequences with scores <0.9 showed ADA incidence of 18%–25%. The computational accuracy exceeded 90%.

2. Antibody–Antigen Affinity Prediction: Prioritizing High-Activity Molecules

Affinity, typically represented by KD, is one of the central indicators related to antibody activity. Conventional experimental measurement is costly and limited in throughput. AbSeek^TM improves early affinity estimation through structure prediction and interface feature modeling.

• Computational logic:An AlphaFold3-like model predicts the three-dimensional structure of the antibody–antigen complex and locates the binding interface between CDR regions and antigen epitopes. A geometric deep learning-based affinity prediction model then extracts structural features of the antibody–antigen interface and predicts binding affinity, expressed as KD.
• Prediction performance:Across 100 monoclonal antibody KD prediction tasks, AbSeek^TM achieved a correlation of 0.6 with SPR results, with prediction deviation below 15%. This outperformed conventional approaches with typical correlation levels of approximately 0.3–0.4.
• Cost value:In a VEGF antibody screening project, AbSeek^TM enabled the identification of a KD<0.1 nM molecule after validating only 20 sequences, compared with 100 sequences required in full-library experimental screening, reducing testing cost by 80%.

3. Blocking Activity Prediction: Early Functional Mechanism Assessment

Blocking activity refers to the ability of an antibody to interrupt antigen–receptor interactions and is usually confirmed through cell-based assays. Traditional validation may take 1–2 months. AbSeek^TM uses structure docking and energy competition calculations to estimate functional activity earlier.

• Workflow:The platform constructs a reference antigen–receptor complex, such as a PD-1/PD-L1 complex; simulates antibody binding to the antigen; calculates the spatial occupancy of the antibody over the antigen–receptor interface; and compares antibody–antigen binding energy with antigen–receptor binding energy to estimate competitive advantage and generate a Blocking prediction value.
• Application validation:In a PD-1/PD-L1 bispecific antibody project, AbSeek^TM generated Blocking predictions for five antibodies that were consistent with subsequent experimental blocking activity results.
• Efficiency gain:The Blocking activity evaluation cycle can be shortened from 1–2 months to approximately one day, creating an earlier decision window for developability optimization.

4. Multi-Parameter Developability Optimization: Reducing Late-Stage Failure Risk

Antibody developability, including aggregation risk, thermal stability, pH stability, and correct multi-chain assembly, is critical for translational success. AbSeek^TM supports early risk assessment and sequence optimization through multi-dimensional computation.

• Aggregation risk prediction:A convolution-attention hybrid neural network trained on aggregation data from more than 100,000 protein sequences predicts protein aggregation propensity from sequence information. In an ADC project, AbSeek^TM predicted high aggregation risk for one candidate monomer, which was later confirmed by SEC-HPLC with an aggregation rate of 18.7%, supporting timely removal of the risk molecule.
• Thermal stability optimization:The TemBERTureTm model predicts antibody Tm values, while point mutation strategies evaluate how amino acid substitutions affect thermal stability. In an anti-HER2 antibody, a computationally guided Asn→Gln mutation increased Tm from 58℃ to 65℃, meeting formulation stability requirements.
• Bispecific antibody mispairing assessment:The AbPair model evaluates the likelihood of natural pairing among different heavy and light chains in bispecific antibody formats, helping filter combinations that are unlikely to pair correctly and thereby improving correct assembly rates.

Practical Value: Improving Both Efficiency and Cost Structure

The computational methods in AbSeek^TM are integrated into Cyagen’s full-chain “computation + experiment” R&D system. The goal is to use computation to guide experiments and experimental feedback to improve models, addressing a common challenge in applying AI tools to antibody discovery.

1. Working with Experimental Platforms to Reduce Ineffective Trial and Error

AbSeek^TM forms a closed loop of computational screening and experimental validation with HUGO-Light^TM common light chain mice and HUGO-Nano^TM nanobody mice.

Case: Claudin 18.2/CD3 bispecific antibody development

A biotech company needed to develop a Claudin 18.2/CD3 bispecific antibody. In a conventional workflow, 200 antibodies would be screened from HUGO-Light^TM mice and validated one by one, requiring approximately 12 months. With AbSeek^TM computational methods:

• 50 high-affinity candidate sequences with KD<0.5 nM were first obtained from the HUGO-Light^TM immune library.
• AbSeek^TM modules were then used for rapid assessment: humanness scoring selected 15 low-immunogenicity candidates, Blocking activity prediction retained 10 candidates with strong functional potential, and developability assessment removed three high-aggregation-risk sequences.
• Only seven sequences required experimental validation to identify a PCC candidate, shortening the development cycle to six months and reducing experimental cost by 70%.

2. Lowering the Barrier to Professional Computational Biology

For emerging biotech companies that lack in-house computational biology teams, AbSeek^TM provides accessible computing services that help antibody R&D teams adopt advanced computational capabilities more easily.

• Visual computing interface:Users can upload antibody sequences without coding and automatically generate humanness scores, KD predictions, and developability risk reports.
• Customized computing solutions:For specialized tasks such as ADCs and bispecific antibodies, AbSeek^TM can support analyses such as conjugation site stability assessment and epitope distance calculation.
• Interpretation support:Professional computational engineers help interpret the biological meaning behind computational reports and guide downstream experimental planning.

Differentiated Strengths of AbSeek^TM Computational Methods

In a rapidly expanding market for AI antibody design tools, the core strength of AbSeek^TM lies in industrial adaptability and experimental verifiability.

• Data advantage:Millions of proprietary experimental records make the models more aligned with industrial antibody development tasks and reduce the risk that models trained only on public data perform well in academic benchmarks but fail in industrial settings.
• Full-workflow coverage:From humanness assessment to affinity prediction, Blocking activity calculation, and developability optimization, AbSeek^TM covers key stages of antibody design without requiring frequent switching between disconnected tools.
• Verifiability:Each computational output can be validated through Cyagen’s experimental platforms, including SPR, DSC, and in vivo efficacy models, forming a computation–experiment closed loop.

Computation as a Driver of the Future Antibody R&D Paradigm

As AI-powered computation evolves from a supporting tool into an important driver of R&D decision-making, antibody discovery is entering a phase in which design cycles may be shortened by 50% and costs reduced by 60%. The computational methods behind AbSeek^TM are not only a technology system, but also a restructuring of the traditional discovery paradigm: antibody design is moving from an experience-driven art toward a data-driven science.

Looking ahead, with the continued integration of high-accuracy multi-chain structure prediction capabilities such as AlphaFold3 and single-cell immune repertoire sequencing data, AbSeek^TM will further explore “zero-experiment” design paths that move closer to designing antibody sequences directly from target structures, while retaining experimental validation as a critical decision layer.

For pharmaceutical companies and biotech teams, the AbSeek^TM intelligent computing platform provides a practical, verifiable, full-workflow antibody computing solution that turns efficiency gains from a concept into measurable project outcomes.